If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Reyvow ® (lasmiditan) tablets CV
50 mg, 100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
REYVOW® (lasmiditan): Pregnancy Registry
There will be a Reyvow (lasmiditan) pregnancy registry in the United States starting in 2021.
A pregnancy registry for lasmiditan will be available in the United States starting in 2021.
Pregnancy or related events can be reported to
the Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov/medwatch, or
Enclosed Prescribing Information
Date of Last Review: June 10, 2020
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 8am - 7pm ET
